SYP and Alzheimer disease: Specifically, in the PFC of humans with AD, we demonstrate greater Akt S473 phosphorylation, greater content of OXPHOS complexes III and V paired with lower OCR through complex I and III, greater AMPA GluA1 and synaptophysin expression, greater anti‐inflammatory IL‐2 content, and lower expression of Iba1 in the gray matter of human AD individuals.